Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)

被引：0
|
作者：
De Boer, R.
Arrieta, O.
Gottfried, M.
Blackhall, F. H.
Raats, J.
Yang, C. H.
Langmuir, P.
Milenkova, T.
Read, J.
Vansteenkiste, J.
机构：
[1] Western Hosp Melbourne, Melbourne, Vic, Australia
[2] INCan, Mexico City, DF, Mexico
[3] Meir Med Ctr, Kefar Sava, Israel
[4] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[5] Panorama Med Ctr, Cape Town, South Africa
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Univ Hosp Leuven, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8010
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
    de Boer, Richard H.
    Arrieta, Oscar
    Yang, Chih-Hsin
    Gottfried, Maya
    Chan, Valorie
    Raats, Johann
    de Marinis, Filippo
    Abratt, Raymond P.
    Wolf, Juergen
    Blackhall, Fiona H.
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1067 - 1074
  • [2] Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)
    de Boer, Richard H.
    Arrieta, Oscar
    Gottfried, Maya
    Blackhall, Fiona H.
    Raats, Johann
    Yang, Chih-Hsin
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S356 - S357
  • [3] Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC); a randomized, double-blind phase III trial
    Vansteenkiste, J.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    de Boer, R. H.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [4] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [5] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Eberhardt, W. E. E.
    Johnson, B. E.
    Sun, Y.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Tada, H.
    Kennedy, S.
    Herbst, R. S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 505 - 505
  • [7] Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
    Hanna, Nasser H.
    Kaiser, Rolf
    Sullivan, Richard N.
    Aren, Osvaldo Rudy
    Ahn, Myung-Ju
    Tiangco, Beatrice
    Voccia, Isabelle
    von Pawel, Joachim
    Kovcin, Vladimir
    Agulnik, Jason
    Gaschler-Markefski, Birgit
    Barrueco, Jose
    Sikken, Patricia
    Schloss, Charles
    Kim, Joo-Hang
    [J]. LUNG CANCER, 2016, 102 : 65 - 73
  • [8] A phase II, double-blind, randomized study of enzastaurin versus placebo concurrently with pemetrexed as second-line therapy in patients with advanced or metastatic non-small cell lung cancer
    von Pawel, Joachim
    Barlesi, Fabrice
    Soria, Jean-Charles
    Bearz, Alessandra
    Barata, Fernando
    Park, Keunchil
    Zhao, Yan D.
    Chouaki, Nadia
    Iscoe, Neill
    Bepler, Gerold
    Chiappori, Alberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S384 - S385
  • [9] Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer
    Zhang Yi-fei
    Chen Zhi-wei
    Lu Shun
    [J]. CHINESE MEDICAL JOURNAL, 2009, 122 (20) : 2472 - 2476
  • [10] Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer
    ZHANG Yifei CHEN Zhiwei LU Shun Shanghai Lung Tumor Clinical Medical CenterChest Hospital Affiliated to Shanghai Jiao Tong UniversityShanghai China
    [J]. 中华医学杂志(英文版), 2009, (20) : 2472 - 2476
12345